A multicenter study to evaluate the disease burden and health economics of inpatients with multiple sclerosis in China

Tan, Ge; Xu, Yuanfu; Wang, Weizhi; Wang, Lihua; Li, Chunyang; Zhang, Xinghu; Zhou, Hongyu; Dong, Hui; Zhang, Meini; Jin, Taiyi; Yang, Huan; Cui, Li-ying; Guo, Li

doi:10.1016/j.msard.2022.103732

Cited by 5 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The medical costs of MS in China in published studies range from 5,042.85 CNY (approximately 711 USD) [25] to 27,655.57 CNY (approximately 3,899 USD) [24]. Our ndings on direct medical costs suggest a higher economic burden than those revealed by other studies in China.…”

Section: Discussionmentioning

confidence: 45%

Disease burden and costs associated with multiple sclerosis in China: A cross-sectional analysis of nationwide survey data

Jia

Qiao

Zhao

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Multiple sclerosis (MS) imposes a huge burden on patients, not only physically, due to progressive disability, but also financially, due to reduced productivity and high utilization of healthcare resources. Little is known about the costs associated with MS for patients in China. This study aimed to estimate the disease burden of MS in China and the economic impact of MS and its association with disability severity, thereby providing empirical data to inform public health decision-making. Methods This was a retrospective, cross-sectional study using a self-reported online survey. Data were collected from MS patients including demographic information, employment status, health-related quality of life, resource utilization, and associated costs. The severity of the disability status of MS patients was identified by a proxy question for the Expanded Disability Status Scale (EDSS). Regression analysis was applied to estimate the association between costs and disease severity. Results A total of 477 MS patients were included in the study. The mean age was 34.5 years, and 65.6% were female. The employment rate was 50.3%. The average total annual costs for an MS patient were approximately 168,228 CNY (23,720 USD) in China. The mean utility value was estimated at 0.808 for patients with EDSS < 4, 0.437 at EDSS 4–6, and 0.017 at EDSS > 6. Total annual costs of MS were 154,673 CNY (21,809 USD) at EDSS < 4, 187,038 CNY (26,372 USD) at EDSS 4–6, and 235,390 CNY (33,190 USD) at EDSS > 6. This study further found a significant association between disability severity and indirect costs due to MS. Conclusions Our findings identified severe disease burden and costs among MS patients in China. Higher costs were imposed on MS patients as the severity of disability increased, and the increase in the economic burden of MS was mainly driven by a dramatic increase in indirect costs. This study highlights the importance of slowing the progression of MS to reduce indirect costs of MS patients and provides empirical data for further policy review and reform.

show abstract

Section: Discussionmentioning

confidence: 45%

Disease burden and costs associated with multiple sclerosis in China: A cross-sectional analysis of nationwide survey data

Jia

Qiao

Zhao

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The morbidity of MS in China is lower than the global, with a prevalence of 3.4 per 100,000 people among males and 6.3 per 100,000 people among females in eight provinces in China mainland, 8,9 7.02 per 100,000 in Taiwan and 4.8 per 100,000 in Hong Kong 9 . In China, the annual direct economic cost was 27,655.57 ± 29,204.25 Chinese Yuan per capita, and the annual indirect cost was 11,299.85 ± 3169.54 Chinese Yuan, according to a study involving 50 centers 7 . In addition to the financial burden caused by the long duration of the disease and high‐priced medications, patients with MS may also be troubled by limited healthcare levels 10 .…”

Section: Introductionmentioning

confidence: 99%

“…MS is crippling and mainly affects young and moderately aged adults, 5 leading to productivity loss and disability 6 . The long duration of MS, difficulty in performing daily activities, and the need for multidisciplinary treatment caused a great burden on individuals, families, and society 7 . The global population of MS was estimated about 2.8 million in 2020, with a prevalence of 35.9 per 100,000 people 8 .…”

Section: Introductionmentioning

confidence: 99%

“… 6 The long duration of MS, difficulty in performing daily activities, and the need for multidisciplinary treatment caused a great burden on individuals, families, and society. 7 The global population of MS was estimated about 2.8 million in 2020, with a prevalence of 35.9 per 100,000 people. 8 In the United States, the total annual economic cost of MS was approximately $28 billion.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gender differences in the burden of multiple sclerosis in China from 1990 to 2019 and its 25‐year projection: An analysis of the Global Burden of Diseases Study

Wang,

Zhang,

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

Background and AimsMultiple sclerosis (MS) is a crippling, chronic, gender‐related disease that causes burdens to individuals and society. China has a considerable and increasing population of MS. We aim to analyze the gender disparities in the burden of MS in China and predict the trends.MethodsThe study was conducted based on the Global Burden of Disease Study 2019. Data on incidence, prevalence, deaths, and disability‐adjusted life years (DALYs) of MS in China from 1990 to 2019 was descriptively analyzed by year, gender, and age group. The Nordpred package in R (version 4.2.2) was used for age‐period‐cohort analysis to predict the all‐ages numbers and age‐standardized rates of incidence, prevalence, deaths, and DALYs in China from 2020 to 2044.ResultsThe number of prevalent cases of MS in 2019 reached 18,143.56 (95% uncertainty intervals [UI]: 13,997.71–22,658.60) in males and 24,427.11 (95% UI: 18,906.02–30,530.21) in females in China. The peak age of prevalence was shifted from 40–44 years in 1990 to 45–49 years in 2019 in females but remained unchanged in males. In contrast to the increased age‐standardized prevalence rate, the age‐standardized death rate (ASDR) and age‐standardized DALYs rate showed downward trends, which were more significant in females. Different from the global, Chinese males showed lower prevalence but higher deaths and DALYs than females for age‐standardized rates and numbers. In the next 25 years, the patient population will remain large and peak around 44,599.78 in 2025–2029. The ASDR, age‐standardized DALYs rate, and DALYs number were expected to decrease. The improvements in deaths and DALYs will be more significant in females.ConclusionMales with MS had a lower prevalence but higher deaths and DALYs than females in China. The ASDR and age‐standardized DALYs rate have reduced over the past 30 years and were expected to continue decreasing, especially in females. The burden of MS will remain notable in the next 25 years.

show abstract

“…The medical costs of MS in China in published studies range from 5042.85 CNY (~711 USD) [ 10 ] to 27,655.57 CNY (~3899 USD) [ 9 ]. Our findings on direct medical costs suggest a higher economic burden than those revealed by other studies in China.…”

mentioning

confidence: 99%

Disease Burden and Costs Associated with Multiple Sclerosis in China: A Cross-sectional Analysis of Nationwide Survey Data

Jia,

Qiao,

Zhao

et al. 2023

Neurosci. Bull.

View full text Add to dashboard Cite

A multicenter study to evaluate the disease burden and health economics of inpatients with multiple sclerosis in China

Cited by 5 publications

References 25 publications

Disease burden and costs associated with multiple sclerosis in China: A cross-sectional analysis of nationwide survey data

Disease burden and costs associated with multiple sclerosis in China: A cross-sectional analysis of nationwide survey data

Gender differences in the burden of multiple sclerosis in China from 1990 to 2019 and its 25‐year projection: An analysis of the Global Burden of Diseases Study

Disease Burden and Costs Associated with Multiple Sclerosis in China: A Cross-sectional Analysis of Nationwide Survey Data

Contact Info

Product

Resources

About